Healthcare

Bioprocessing

The healthcare industry is seeing an increased emphasis on emerging therapeutic modalities such as cell and gene therapy. But the ecosystem required to support these sectors is still young and fragmented.

Working with businesses across this developing sector, we support the growth of cutting-edge companies that are producing and distributing vaccines, therapeutics, antibiotics, diagnostics and more. With extensive experience in biopharma and adjacent areas like pharma services, our investment professionals partner with companies focused on large molecule therapeutics—a growing and vital component of biopharma.

We believe there is substantial opportunity to invest in the large molecule ecosystem to help accelerate the development, manufacturing and distribution of lifesaving therapeutics.

Megan Preiner Managing Director

Insights

Bioprocessing: THL’s Newest Healthcare Sector Focus

THL’s Healthcare team was among 2,000 industry leaders in attendance at Advanced Therapies Week (ATW) — one of the largest and most immersive conferences for cell and gene therapy (CGT) — and one thing is clear: the large molecule therapeutics sector remains an exciting place to be. Valued at $300 billion, this market is rapidly growing,

Healthcare (HC)

Insights

2023 Healthcare Trends and Our Outlook for 2024

Operational Challenges, Patent Cliffs & Biotech Funding Slowdown, and Generative AI Define 2023; Encouraging Prospects Emerge for 2024 Key Takeaways: The healthcare industry experienced a significant transformation in 2023, driven by three defining trends: operational challenges due to staffing shortages and evolving payment models, looming patent cliffs for pharma manufacturers and a biotech funding slowdown that impacted

Healthcare (HC)